[1] DOLEN Y, GUNAYDIN G, ESENDAGLI G, et al. Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma. Cell Immunol. 2015;295(1):29-35.
[2] CONDAMINE T, GABRILOVICH DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011; 32(1):19-25.
[3] SAFARI E, GHORGHANLU S, AHMADI-KHIAVI H, et al. Myeloid-derived suppressor cells and tumor: Current knowledge and future perspectives. J Cell Physiol. 2019;234(7):9966-9981.
[4] RODRIGUEZ PC, QUICENO DG, OCHOA AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007;109(4):1568-1573.
[5] NAKAMURA T, NAKAO T, YOSHIMURA N, et al. Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells. Am J Transplant. 2015;15(9):2364-2377.
[6] SHEVYREV D, TERESHCHENKO V. Treg Heterogeneity, Function, and Homeostasis. Front Immunol. 2020;10:3100.
[7] GIALLONGO C, TIBULLO D, PARRINELLO NL, et al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget. 2016;7(52):85764-85775.
[8] MEI Y, LI Z, ZHANG Y, et al. Low miR-210 and CASP8AP2 expression is associated with a poor outcome in pediatric acute lymphoblastic leukemia. Oncol Lett. 2017;14(6):8072-8077.
[9] TOMIĆ S, JOKSIMOVIĆ B, BEKIĆ M, et al. Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets. Front Immunol. 2019;10:475.
[10] OKANO S, ABU-ELMAGD K, KISH DD, et al. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients. Am J Transplant. 2018;18(10): 2544-2558.
[11] QU J, LIU L, XU Q, et al. CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production. Int J Cancer. 2019;145(8):2225-2237.
[12] YU J, DU W, YAN F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783-3797.
[13] LI F, ZHAO Y, WEI L, et al. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther. 2018;19(8):695-705.
[14] YANG F, YU X, ZHOU C, et al. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 2019;15(4):e1007690.
[15] WEBER R, GROTH C, LASSER S, et al. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol. 2021; 359:104254.
[16] TARTOUR E, PERE H, MAILLERE B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30(1):83-95.
[17] WEBER R, RIESTER Z, HÜSER L, et al. IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. J Immunother Cancer. 2020;8(2):e000949.
[18] SUN C, MEZZADRA R, SCHUMACHER TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434-452.
[19] RUAN WS, FENG MX, XU J, et al. Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis. Front Immunol. 2020;11:1299.
[20] GAO W, DEMIRCI G, STROM TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation. 2003;76(6):994-999.
[21] NAKAMURA T, NAKAO T, ASHIHARA E, et al. Myeloid-derived Suppressor Cells Recruit CD4(+)/Foxp3(+) Regulatory T Cells in a Murine Cardiac Allograft. Transplant Proc. 2016;48(4):1275-1278.
[22] KiM W, CHU TH, NIENHÜSER H, et al. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2021;160(3):781-796.
[23] WANG Z, ZHU F, WANG J, et al. Increased CD14(+)HLA-DR(-/low) Myeloid-Derived Suppressor Cells Correlate With Disease Severity in Systemic Lupus Erythematosus Patients in an iNOS-Dependent Manner. Front Immunol. 2019;10:1202.
[24] GARCÍA-ORTIZ A, SERRADOR JM. Nitric Oxide Signaling in T Cell-Mediated Immunity. Trends Mol Med. 2018;24(4):412-427.
[25] XUE Q, YAN Y, ZHANG R, et al. Regulation of iNOS on Immune Cells and Its Role in Diseases. Int J Mol Sci. 2018;19(12):3805.
[26] BRONTE V, BRANDAU S, CHEN SH, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.
[27] ZHENG Y, TIAN X, WANG T, et al. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Mol Cancer. 2019;18(1):61.
[28] TIAN X, ZHENG Y, YIN K, et al. LncRNA AK036396 Inhibits Maturation and Accelerates Immunosuppression of Polymorphonuclear Myeloid-Derived Suppressor Cells by Enhancing the Stability of Ficolin B. Cancer Immunol Res. 2020;8(4):565-577.
[29] DENG H, WU L, LIU M, et al. Bone Marrow Mesenchymal Stem Cell-Derived Exosomes Attenuate LPS-Induced ARDS by Modulating Macrophage Polarization Through Inhibiting Glycolysis in Macrophages. Shock. 2020; 54(6):828-843.
[30] Yang H, Wu L, Deng H, et al. Anti-inflammatory protein TSG-6 secreted by bone marrow mesenchymal stem cells attenuates neuropathic pain by inhibiting the TLR2/MyD88/NF-kappaB signaling pathway in spinal microglia. J Neuroinflammation. 2020;17(1):154.
[31] YANG H, TIAN W, WANG S, et al. TSG-6 secreted by bone marrow mesenchymal stem cells attenuates intervertebral disc degeneration by inhibiting the TLR2/NF-κB signaling pathway. Lab Invest. 2018;98(6):755-772.
[32] WANG G, ZHANG S, WANG F, et al. Expression and biological function of programmed death ligands in human placenta mesenchymal stem cells. Cell Biol Int. 2013;37(2):137-148.
[33] PAPAEMMANUIL E, GERSTUNG M, MALCOVATI L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-3627.
[34] NOLL JE, WILLIAMS SA, TONG CM, et al.Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2014;99(1):163-171.
[35] LONG X, LI X, LI T, et al. Umbilical cord mesenchymal stem cells enhance the therapeutic effect of imipenem by regulating myeloid-derived suppressor cells in septic mice. Ann Transl Med. 2021;9(5):404.
[36] TIAN J, HONG Y, ZHU Q, et al. Mesenchymal Stem Cell Enhances the Function of MDSCs in Experimental Sjogren Syndrome. Front Immunol. 2020;11:604607.
[37] CHEUNG TS, DAZZI F. Mesenchymal-myeloid interaction in the regulation of immunity. Semin Immunol. 2018;35:59-68.
[38] YANG S, WEI Y, SUN R, et al. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation. Cytotherapy. 2020;22(12):718-733.
[39] KÖSTLIN N, OSTERMEIR AL, SPRING B, et al. HLA-G promotes myeloid-derived suppressor cell accumulation and suppressive activity during human pregnancy through engagement of the receptor ILT4. Eur J Immunol. 2017;47(2):374-384.
[40] ZHANG Z, NIU L, TANG X, et al. Mesenchymal stem cells prevent podocyte injury in lupus-prone B6.MRL-Faslpr mice via polarizing macrophage into an anti-inflammatory phenotype. Nephrol Dial Transplant. 2018;33(11):2069.
[41] LIU R, SU D, ZHOU M, et al. Umbilical cord mesenchymal stem cells inhibit the differentiation of circulating T follicular helper cells in patients with primary Sjogren’s syndrome through the secretion of indoleamine 2,3-dioxygenase. Rheumatology (Oxford). 2015;54(2):332-342.
[42] LI X, XU Z, BAI J, et al. Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Induce T Lymphocyte Apoptosis and Cell Cycle Arrest by Expression of Indoleamine 2, 3-Dioxygenase. Stem Cells Int. 2016;2016:7495135.
[43] LEE HJ, KO JH, JEONG HJ, et al. Mesenchymal stem/stromal cells protect against autoimmunity via CCL2-dependent recruitment of myeloid-derived suppressor cells. J Immunol. 2015;194(8):3634-3645.
[44] QI J, TANG X, LI W, et al. Mesenchymal stem cells inhibited the differentiation of MDSCs via COX2/PGE2 in experimental sialadenitis. Stem Cell Res Ther. 2020;11(1):325.
[45] NÉMETH K, LEELAHAVANICHKUL A, YUEN PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42-49.
[46] LUK F, DE WITTE SF, KOREVAAR SS, et al. Inactivated Mesenchymal Stem Cells Maintain Immunomodulatory Capacity. Stem Cells Dev. 2016;25(18): 1342-1354.
[47] WANG T, WEN Y, FAN X. Myeloid-derived suppressor cells suppress CD4+ T cell activity and prevent the development of type 2 diabetes. Acta Biochim Biophys Sin (Shanghai). 2018;50(4):362-369.
[48] ALTANEROVA U, JAKUBECHOVA J, BENEJOVA K, et al. Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes. Int J Cancer. 2019;144(4):897-908.
[49] GARCIA-GOMEZ A, DE LAS RIVAS J, OCIO EM, et al. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget. 2014;5(18):8284-8305.
|